Merck & Co. (MRK) Q4 and Annual 2025 Earnings
Merck & Co. reported Q4 2025 revenue of $16.4B (+5.0% YoY), beat analyst consensus of $16.2B by $200.9M. Diluted EPS came in at $2.04 (+18.6% YoY), beat the $2.01 consensus by $0.03. Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health.
Financial Snapshot
Trailing eight quarters through Q4 2025
Q4 2025 Earnings FAQ
Common questions about Merck & Co.'s Q4 2025 earnings report.
Merck & Co. (MRK) reported Q4 2025 earnings on February 3, 2026 before market open.
Merck & Co. reported revenue of $16.4B and diluted EPS of $2.04 for Q4 2025.
Revenue beat the consensus estimate of $16.2B by $200.9M. EPS beat the consensus estimate of $2.01 by $0.03.
Compared to the same quarter a year prior, revenue grew 5.0% from $15.6B a year earlier and diluted EPS grew 18.6% from $1.72.
Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health. Segment-level financials are available on the company's metrics pages.
You can read the 8-K earnings release (0001104659-26-009495) and the 10-K periodic report (0000310158-26-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.